ClinicalTrials.gg
RecruitingNCT07120425Updated Sep 17, 2025

A Study of IBI3032 in Healthy Participants

A Phase 1 interventional study of IBI3032 and placebo in Healthy, sponsored by Fortvita Biologics (USA)Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Fortvita Biologics (USA)Inc. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled Phase I clinical study evaluating the safety, tolerability, and PK of a single dose of IBI3032 in healthy participants. This is a single ascending dose (SAD) study. Approximately 32 healthy participants are expected to be enrolled in this study.

The screening period is 4 weeks. Eligible participants will be divided into 4 cohorts. Each cohort consisted of 8 healthy participants who will be randomized in a 6:2 ratio to receive a single dose of IBI3032 or placebo. The safety follow-up period is 15 days. This study is for research purposes only, and is not intended to treat any medical condition.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Fortvita Biologics (USA)Inc. is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or females, as determined by medical history
  • Have safety laboratory results within normal reference ranges

Exclusion criteria

Exclusion Criteria:

  • Have known allergies toIBI3032, glucagon-like peptide-1 (GLP-1) analogs, related compounds
  • Abnormal (ECG) at screening
  • Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Single dose4 of IBI3032 administered orally.

    dose4 IBI3032

    Drug: IBI3032

  • Experimental
    Single dose3 of IBI3032 administered orally.

    dose3 IBI3032

    Drug: IBI3032

  • Placebo comparator
    Single dose4 of placebo administered orally.

    dose4 placebo

    Drug: placebo

  • Experimental
    Single dose1 of IBI3032 administered orally.

    dose1 IBI3032

    Drug: IBI3032

  • Placebo comparator
    Single dose3 of placebo administered orally.

    dose3 placebo

    Drug: placebo

  • Placebo comparator
    Single dose1 of placebo administered orally.

    dose1 placebo

    Drug: placebo

  • Experimental
    Single dose2 of IBI3032 administered orally.

    dose2 IBI3032

    Drug: IBI3032

  • Placebo comparator
    Single dose2 of placebo administered orally.

    dose2 placebo

    Drug: placebo

Interventions

  • IBI3032: Method of administration: oral, fasted administration.

  • Drugplacebo

    Placebo (without active ingredients) Method of administration: oral, fasted administration.

06

What researchers measure

Primary outcomes

  1. Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Day 15

  2. Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

    A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Day 15

  3. Number of Participants with adverse events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

    Time frame: Baseline up to Day 15

Secondary outcomes

  1. Under the Serum Concentration-time Curve (AUC) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  2. maximum concentration (Cmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  3. time to maximum concentration (Tmax) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  4. clearance (CL) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  5. apparent volume of distribution (V) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

  6. elimination half-life (T1/2) of IBI3032

    To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.

    Time frame: Predose up to 168 hours postdose

07

Study locations

1 of 1 sites recruiting
  • ICON Clinical Research
    Lenexa, Kansas 66219, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Nov 2025, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 13, 2025
StartActual
Sep 10, 2025
Primary completionEst.
Nov 13, 2025
CompletionEst.
Nov 13, 2025
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07120425
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Sep 10, 2025
Primary completion
Nov 13, 2025 (estimated)
Completion
Nov 13, 2025 (estimated)
Last update
Sep 17, 2025

Study contacts

lily Zhang
Contact
lily.zhang@innoventbio.com
13603216253

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI3032

Start the discussion